EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Hemodynamic Management in Burn Patients with Vasopressor-Dependent Sepsis: A Preliminary Exploratory Retrospective Cohort Study

Martha Bara, Christina-Chrysanthi Theocharidou, Maria Gkogkou, Paschalina Kontou, Andreas Papadimos, Sophia Papadopoulou, Georgia Pitsiou, Athina Lavrentieva

European Burn Journal · 2026-11-06 · 7 (4) · 55

DOI: 10.3390/ebj7040055 ↗
AbstractBibliografische Angaben

Abstract

Background: Sepsis remains a leading cause of late mortality in critically ill burn patients. The optimal hemodynamic strategy, including vasopressor combinations, corticosteroids, and landiolol therapy, remains incompletely defined in this population. Objective: To examine factors associated with landiolol therapy, vasopressor strategies, and corticosteroid use in burn patients with vasopressor-dependent sepsis, and to evaluate their relationship with organ dysfunction and clinical outcomes. Methods: We conducted a preliminary exploratory retrospective cohort study in a specialized burn intensive care unit (ICU) over a three-year period (2022–2024). All mechanically ventilated adult burn patients who developed sepsis requiring vasopressor support during ICU stay were included. The primary exposure of interest was landiolol therapy; five outcomes were assessed for this exposure (ventilator-free days at day 28 after sepsis onset, duration of mechanical ventilation after sepsis onset, ICU length of stay after sepsis onset, acute kidney injury [AKI] after sepsis, and ICU mortality). Hydrocortisone administration and dual vasopressor therapy with norepinephrine plus vasopressin were evaluated as secondary descriptive exposures. Results: Thirty-one patients were included (mean age 55.8 ± 15.3 years; mean TBSA 40.2 ± 13.3%). ICU mortality was 35.5% (11/31). Landiolol was administered in 41.9% of patients; all treated patients were in sinus tachycardia (heart rate 111–140 beats/min), whereas all untreated patients had heart rates 0.99), ICU length of stay after sepsis onset (41 [21–62] vs. 56 [15–106.25] days; multiplicity-adjusted p > 0.99), AKI (2/13 vs. 5/18; OR 0.47, 95% CI 0.08–2.93; multiplicity-adjusted p > 0.99), and ICU mortality (6/13 vs. 5/18; OR 2.23, 95% CI 0.50–10.00; multiplicity-adjusted p > 0.99). The shorter total mechanical ventilation duration in landiolol-treated patients (24 [7–38] vs. 53 [18.75–79.75] days) reflected shorter ventilation before sepsis onset (6 [3–16] vs. 16.5 [10–36.75] days) and the competing risk of early death (six of eleven deaths occurred within 28 days of sepsis onset). Dual vasopressor therapy (25.8%) and hydrocortisone (19.4%) identified phenotypes of greater shock severity. Conclusions: In this small preliminary retrospective cohort, protocolized landiolol therapy in sinus-tachycardic patients was feasible and achieved heart-rate targets, but was not associated with detectable differences in clinical outcomes. These exploratory findings warrant adequately powered prospective studies in this population.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →